Riomet ER™ oral suspension, a liquid formulation of extended-release metformin, has been made available by Sun Pharma. The treatment is indicated for use as an adjunct to diet and exercise to improve glycemic control in patients 10 years of age and older with type 2 diabetes mellitus.
The product is supplied as a powder for oral suspension which must be reconstituted with the accompanying diluent prior to dispensing; both the powder and diluent contain metformin HCl. Following reconstitution, the volume of the oral suspension is 473mL (16 oz) containing 500mg/5mL metformin HCl equivalent to 389.95mg metformin base. Treatment should be administered using the dosing cap provided in the package.
Riomet ER is supplied in cartons containing 1 bottle of drug pellets, 1 bottle of diluent, and 1 dosing cup. It is available in both strawberry and grape flavors. The shelf-life of the constituted oral suspension is 100 days.
“As the fourth Sun Pharma product designed to address the needs of the 40% of US adults who cannot or will not swallow solid medications, Riomet ER reflects our continued commitment to providing alternative formulations to underserved patient populations,” said Abhay Gandhi, CEO, North America, Sun Pharma.
For more information visit riometer.com.
This article originally appeared on MPR